On Monday, VMware, Inc (NYSE:VMW)’s shares declined -0.94% to $84.27.
Yesterday, VMware, Inc (VMW), declared two new open source projects built to enable enterprise adoption of cloud-native applications — Project Lightwave, an identity and access administration project that will extend enterprise-scale and security to cloud-native applications; and Project Photon, a lightweight Linux operating system optimized for cloud-native applications.
Designed to assist enterprise developers securely build, deploy and manage cloud-native applications, these new open source projects will integrate into VMware’s unified platform for the hybrid cloud — creating a consistent environment across the private and public cloud to support cloud-native and traditional applications. By open sourcing these projects, VMware will work with a broad ecosystem of partners and the developer community to drive common standards, security and interoperability within the cloud-native application market — leading to improved technology and greater customer choice.
“Through these projects VMware will deliver on its promise of support for any application in the enterprise — counting cloud-native applications — by extending our unified platform with Project Lightwave and Project Photon,” said Kit Colbert, vice president and chief technology officer for Cloud-Native Applications, VMware, Inc. “Used together, these new open source projects will provide enterprises with the best of both worlds. Developers benefit from the portability and speed of containerized applications, while IT operations teams can maintain the security and performance required in recently’s business environment.”
VMware, Inc. provides virtualization infrastructure solutions in the United States and internationally. The company’s virtualization infrastructure solutions comprise a suite of products designed to deliver a software-defined data center (SDDC), run on industry-standard desktop computers and servers, and support a range of operating system and application environments, in addition to networking and storage infrastructures.
Coronado Biosciences Inc (NASDAQ:CNDO)’s shares dropped -0.92% to $4.30, during the last trading session on Monday.
On April 2, Coronado Biosciences Inc (CNDO), has formed a new partner company, DiaVax Biosciences, to develop novel immunotherapies for the prevention and treatment of cytomegalovirus (CMV), a common virus that affects people of all ages. According to the U.S. Centers for Disease Control and Prevention (CDC), while CMV is typically asymptomatic in healthy individuals, it can cause serious, often life-threatening disease in those with weakened or uneducated immune systems (counting developing fetuses exposed to the virus in utero).
The licensed immunotherapies were developed in the laboratory of Don J. Diamond, Ph.D., Chair of the Department of Experimental Therapeutics at City of Hope National Medical Center in Duarte, California. Dr. Diamond will chair the Scientific Advisory Board of DiaVax. Under the contract with City of Hope, DiaVax secured worldwide rights to two T-cell immunotherapeutic vaccines for controlling CMV in allogeneic hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients. Known as Triplex and PepVax, the programs are predictable to enter Phase II clinical studies later this year and are supported by grants from the National Cancer Institute. In connection with the licensing of Triplex and PepVax, DiaVax further reached an option contract with City of Hope for exclusive worldwide rights to Pentamer, a universal immunotherapeutic vaccine being developed for the prevention of CMV transmission in utero. If DiaVax exercises its option, and successfully develops and commercializes PepVax, Triplex and Pentamer, City of Hope could receive in excess of $100MM in upfront, milestone and other payments.
Coronado Biosciences, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. Its principal pharmaceutical product candidates in clinical development comprise Trichuris suis ova or CNDO-201, a biologic comprising the microscopic eggs of the porcine whipworm for the treatment of autoimmune diseases, such as Cohn’s disease, ulcerative colitis, or autism spectrum disorder; and CNDO-109, a biologic that activates the immune system’s natural killer cells to seek and destroy cancer cells for the treatment of acute myeloid leukemia.
At the end of Monday’s trade, Avon Products, Inc (NYSE:AVP)‘s shares dipped -0.92% to $8.66.
On April 13, Avon Products, Inc (AVP), declared that it has decided to postpone to Fall 2015 its Investor Day that the Company was originally planned to host on May 13, 2015. The decision to postpone the meeting follows the recent appointment of James S. Scully as the Company’s Chief Financial Officer, to allow the Company adequate time to prepare for a more robust talk about at the meeting. Further details, counting webcast information, will be declared closer to the event.
Avon will provide an update on its turnaround progress when it reports first-quarter 2015 financial results on April 30, 2015.
Avon Products, Inc. manufactures and markets beauty and related products worldwide. It offers beauty products, such as skincare, and personal care products, in addition to fragrances and color cosmetics; and fashion and home products comprising of jewelry, watches, apparel, footwear, accessories, gift and decorative products, housewares, entertainment and leisure products, children’s products, and nutritional products.
Ocwen Financial Corp (NYSE:OCN), ended its Monday’s trading session with -0.91% loss, and closed at $7.63.
Yesterday, Ocwen Financial Corp (OCN) , hosted its sixth Annual Housing Advocacy and Policy Forum on Thursday, April 16, 2015 in Washington D.C. Ocwen’s 2015 Forum brought together key stakeholders to share their insight and work together on important issues affecting recently’s housing industry. Attendees of the Forum comprised of senior officials from housing advocacy and policy groups, the mortgage industry, and federal government agencies.
Ocwen’s President and CEO, Ronald Faris, offered the group with an update on Ocwen and the steps the company continues to take to assist borrowers. Attendees at the Forum also heard from two of Ocwen’s newest Board Members, Phyllis Caldwell, who was a senior official at the U.S. Department of the Treasury overseeing the Department’s HAMP program, and Dr. DeForest Soaries, Jr., who served under President George W. Bush and was a former Secretary of State in New Jersey.
Panelists during these roundtable discussions included representatives from:
- S. Department of the Treasury
- CoreLogic
- Consumer Federation of America
- Center for American Progress
- Mortgage Bankers Association
- Ocwen Financial Corporation
- Ocwen Board of Directors
“While we are still recovering from the housing crisis, there are already lessons that can be learned. One of those lessons is the importance of financial and mortgage counseling,” Ms. Caldwell said. “It’s clear that borrowers who worked with housing counselors throughout the process of buying a home and paying their mortgage were not only less likely to have been taken advantage of by predatory lenders, but they were also more likely to raise their hand for assist when there was a problem. We cannot underestimate the value of financial counseling. And I’m proud to say that Ocwen understands that and has made its partnership with community organizations and counselors a priority.”
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
